In line with the AIM Rules, the Board of LiDCO (AIM: LID), the cardiovascular monitoring company, today announces that it has drawndown a further instalment of the US$2 million three year secured revolving convertible loan raised on 10th August 2005 from Laurus Master Fund, Ltd. (“Laurus”), which is now fully utilised.

Notes to Editors

About Laurus Capital Management LLC

Laurus is a US based financial institution that provides finance to small and micro cap growth companies. Their flexible financing solutions are designed to help build cash reserves and enable management to focus on operations and strategic growth opportunities.

About LiDCO Group Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.